NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $10.08 -0.02 (-0.20%) Closing price 04:00 PM EasternExtended Trading$10.08 0.00 (0.00%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$10.00▼$10.2250-Day Range$9.70▼$12.7852-Week Range$9.58▼$16.53Volume86,615 shsAverage Volume53,167 shsMarket Capitalization$154.25 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Read More… Joint Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 69% of companies evaluated by MarketBeat, and ranked 305th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Joint's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.73% of the outstanding shares of Joint have been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Joint has recently decreased by 0.95%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.73% of the outstanding shares of Joint have been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Joint has recently decreased by 0.95%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.75 News SentimentJoint has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Joint this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesC3 AI and Baker Hughes Renew and Expand Joint Venture AgreementMay 28 at 4:18 PM | businesswire.comThe Joint Corp. appoints new director for growth strategyMay 24, 2025 | uk.investing.com“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 28, 2025 | Brownstone Research (Ad)JYNT The Joint Corp.May 24, 2025 | seekingalpha.comPennantPark Floating Rate Capital Ltd.'s Unconsolidated Joint Venture, PennantPark Senior Secured Loan Fund I LLC Completes the Reset of its $315.8 Million Securitization, Lowering the Cost of FinancingMay 22, 2025 | globenewswire.comThe Joint Corp. Appoints Christopher M. Grandpre as New Director to Support Growth InitiativesMay 22, 2025 | quiverquant.comThe Joint Corp. Announces Christopher M. Grandpre Elected as DirectorMay 22, 2025 | globenewswire.comJoint (NASDAQ:JYNT) versus Alpha Modus Holdings, Inc. - Class A Common Stock (NASDAQ:AMOD) Head-To-Head ReviewMay 22, 2025 | americanbankingnews.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $10.63 at the beginning of the year. Since then, JYNT shares have decreased by 4.8% and is now trading at $10.1250. View the best growth stocks for 2025 here. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The company earned $13.08 million during the quarter, compared to the consensus estimate of $13.02 million. Joint had a negative net margin of 13.95% and a positive trailing twelve-month return on equity of 8.24%. Read the conference call transcript. When did Joint IPO? Joint (JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Top institutional shareholders of Joint include Skylands Capital LLC (4.91%), Alta Fox Capital Management LLC (2.63%), Topline Capital Management LLC (2.47%) and Goldman Sachs Group Inc. (2.22%). View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/08/2025Today5/28/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Patent owners & lessors Sub-IndustryTrading Current SymbolNASDAQ:JYNT CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees320Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$16.00 Low Stock Price Target$15.00 Potential Upside/Downside+52.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E Ratio92.36 P/E GrowthN/ANet Income-$9.75 million Net Margins-13.95% Pretax Margin-4.59% Return on Equity8.24% Return on Assets2.33% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$52.79 million Price / Sales2.95 Cash Flow$0.65 per share Price / Cash Flow15.65 Book Value$1.68 per share Price / Book6.05Miscellaneous Outstanding Shares15,303,000Free Float10,459,000Market Cap$155.48 million OptionableOptionable Beta1.54 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:JYNT) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe trade war twist nobody saw comingThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.